Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Autologous Co-stimulation-impaired Dendritic Cells for Type 1 Diabetes Mellitus (T1DM) Therapy: A Sequential Open Label Phase IB Safety Assessment/ Randomized, Double-blind Phase IIA Efficacy Trial to Maintain and Improve Functional Beta Cell Mass in New Onset Disease T1DM Patients

NCT01947569 is registered in ClinicalTrials.gov with DiaVacs, Inc. as lead sponsor.

NCT NCT01947569
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01947569 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Autologous Co-stimulation-impaired Dendritic Cells for Type 1 Diabetes Mellitus (T1DM) Therapy: A Sequential Open Label Phase IB Safety Assessment/ Randomized, Double-blind Phase IIA Efficacy Trial to Maintain and Improve Functional Beta Cell Mass in New Onset Disease T1DM Patients
Lead sponsor
DiaVacs, Inc.
Phase
Phase 1/2
Overall status
Unknown status
Start date
October 31, 2013
Completion date
Not reported
Enrollment
90 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

treatment of type i diabetes mellitus.